Trials / Recruiting
RecruitingNCT07370207
Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region
A Phase 2 Multi-center, Randomized, Open-label Study to Assess the Efficacy and Safety of AHB-137 in Nucleos(t)Ide Analogue-treated Participants With HBeAg Negative Chronic Hepatitis B in the Asia Pacific Region
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 84 (estimated)
- Sponsor
- AusperBio Therapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is a randomized, open-label, multicenter phase 2 clinical trial to evaluate the efficacy and safety of AHB-137 injection in participants with HBeAg-negative CHB treated with NAs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AHB-137 | Subcutaneous injection |
Timeline
- Start date
- 2026-03-06
- Primary completion
- 2028-12-31
- Completion
- 2028-12-31
- First posted
- 2026-01-27
- Last updated
- 2026-04-13
Locations
8 sites across 6 countries: Australia, China, New Zealand, Singapore, South Korea, Taiwan
Source: ClinicalTrials.gov record NCT07370207. Inclusion in this directory is not an endorsement.